Company Overview and News

2
CDR / Cedar Realty Trust, Inc. FORM 8-K (Current Report)

2018-06-12 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
CDR

4
CDR / Cedar Realty Trust, Inc. FORM 8-K (Current Report)

2018-05-07 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
CDR

39
Whitestone Comments on ISS Recommendation

2018-05-04 globenewswire
HOUSTON, May 04, 2018 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today issued the following statement in response to a report issued by Institutional Shareholder Services (“ISS”) in connection with the Company’s 2018 Annual Meeting of Shareholders (the “Annual Meeting”) to be held on May 17, 2018.
REG KIM.PRI RPT.PRD BFS.PRC UBP.PRH WSR UBP.PRF UBP.PRG BFS.PRD UE.WI BFS.PRA KRG KIM.PRM BFS.PRB KIM.PRL KIM.PRK KIM.PRJ DDR.PRJ UBP AKR DDR.PRK DDR.PRA FRT.PRC KIM WRI.PRD UBA REG.PRG DDR REG.PRF CDR RPT ROIC UE FRT BRX CDR.PRB CDR.PRC BFS WRI

39
Whitestone REIT Mails Letter to Shareholders

2018-05-04 globenewswire
HOUSTON, May 04, 2018 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) announced today that it is mailing a letter to shareholders in connection with Whitestone’s upcoming 2018 Annual Meeting of Shareholders to be held on May 17, 2018. The definitive proxy statement and other important information related to the annual meeting can be found on Whitestone’s website at www.
REG KIM.PRI RPT.PRD BFS.PRC UBP.PRH WSR UBP.PRF UBP.PRG BFS.PRD UE.WI BFS.PRA KRG KIM.PRM BFS.PRB KIM.PRL KIM.PRK KIM.PRJ DDR.PRJ UBP AKR DDR.PRK DDR.PRA FRT.PRC KIM WRI.PRD UBA REG.PRG DDR REG.PRF CDR RPT ROIC KSBO UE FRT BRX CDR.PRB CDR.PRC BFS WRI

2
Cedar Realty Trust's (CDR) CEO Bruce Schanzer on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Cedar Realty Trust, Inc. (NYSE:CDR) Q1 2018 Earnings Conference Call May 1, 2018 5:00 AM ET
CDR CDR.PRB CDR.PRC

2
CDR / Cedar Realty Trust, Inc. 10-Q (Quarterly Report)

2018-05-03 sec.gov
cdr-10q_20180331.htm UNITED STATES
CDR

2
CDR / Cedar Realty Trust, Inc. 8-K (Current Report)

2018-05-03 sec.gov
cdr-8k_20180503.htm UNITED STATES
CDR

39
Whitestone REIT Files Investor Presentation and Mails Letter to Shareholders

2018-04-25 globenewswire
HOUSTON, April 25, 2018 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today announced that it has filed an investor presentation and has mailed a letter to shareholders in connection with Whitestone’s upcoming 2018 Annual Meeting of Shareholders (“2018 Annual Meeting”) to be held on May 17, 2018.
REG KIM.PRI RPT.PRD BFS.PRC UBP.PRH WSR UBP.PRF UBP.PRG BFS.PRD UE.WI BFS.PRA KRG KIM.PRM BFS.PRB KIM.PRL KIM.PRK KIM.PRJ DDR.PRJ UBP AKR DDR.PRK DDR.PRA FRT.PRC KIM WRI.PRD UBA REG.PRG DDR REG.PRF CDR RPT ROIC KSBO UE FRT BRX CDR.PRB CDR.PRC BFS WRI

2
With Activist Campaign Settled, Sexual Harassment Lawsuit Against Cedar Realty Trust Continues - ValueWalk

2018-04-19 valuewalk
As the “Me Too” movement was getting off the ground this past fall, an activist hedge fund campaign was underway to oust the president of Cedar Realty Trust (NYSE:CDR) a Port Washington, NY-based Real Estate Investment Trust that owns and operates nearly $670 million in primarily shopping malls located in the Washington DC to Boston beltway. While the dispute with the activist hedge fund, Snow Park Capital Partners, has been settled, what remains is a sexual harassment lawsuit that is approaching a pivotal moment in court.
CDR CDR.PRB CDR.PRC

2
Cedar Realty Trust Chief Faces Sexual-Harassment Allegations - WSJ

2018-04-17 wsj
A Brooklyn judge will decide whether to allow a sexual-harassment and pay-discrimination lawsuit filed by former Cedar Realty Trust Inc. Chief Operating Officer Nancy Mozzachio against CEO Bruce Schanzer to proceed.
CDR CDR.PRB CDR.PRC

3
CDR / Cedar Realty Trust, Inc. 2018 PROXY STATEMENT

2018-04-02 sec.gov
2018 Proxy Statement Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CDR

39
7
Portfolio Review: Dividend Yields On Cost

2018-03-20 seekingalpha
Yield on cost is a great metric to measure how well a dividend growth stock is performing.
CDR TNTTF CDR.PRB CDR.PRC TD TD

2
CDR / Cedar Realty Trust, Inc. 2018 PROXY STATEMENT

2018-03-14 sec.gov
2018 Proxy Statement Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CDR

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

3h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to CDR / Cedar Realty Trust, Inc. on message board site Silicon Investor.

NCDR CALDERA RESOURCES - CDR.T
CDRD (CD Radio) Caldarau0027s Diamond CDR,M
Verify of a CDR CD Radio (CDRD) A FLOOD OF STOCK
Caldera Resources Inc.
CUSIP: 150602209